

Metathesis-based synthesis of 3-methoxy α,β -unsaturated lactones: total synthesis of (*R*)-kavain and of the C1–C6 fragment of jerangolid D

Jiří Pospíšil, István E. Markó *

Université Catholique de Louvain, Département de Chimie, Bâtiment Lavoisier, Place Louis Pasteur 1, B-1348 Louvain-la-Neuve, Belgium

Received 24 October 2007; revised 19 December 2007; accepted 20 December 2007

Available online 25 December 2007

Abstract

The total synthesis of (*R*)-kavain and of the C1–C6 fragment of jerangolid D has been achieved in nine and seven steps, respectively, from commercially available dimethyl D-malate. A metathesis reaction of vinyl ethers and a sulfoxide-modified Julia olefination have been employed as the key steps.

© 2007 Elsevier Ltd. All rights reserved.


Keywords: Kavain; Jerangolid D; Metathesis; Julia olefination; Sulfoxide-modified Julia olefination

A wide variety of natural products contain a lactone core in their structures. In many cases, these compounds display antitumor activities and the presence of an *endo*- or *exo*-cyclic α,β -unsaturated lactone¹ typically confers to the molecule some antineoplastic activities (among others).²

As a part of our ongoing research program toward the efficient synthesis of natural products possessing anticancer and antifungal properties, we became interested in the development of novel approaches for the assembly of various lactone-bearing subunits. Our initial efforts in this field culminated recently in the establishment of two novel strategies leading to *exo*-methylenelactones. More recently, the synthesis of 3-methoxy α,β -unsaturated lactones of the general structure **1** was targeted.³

We became attracted by this particular class of lactones because of their presence in various natural products, such as kavain **2** and jerangolid D **3** (Scheme 1).

Kavain **2** belongs to the group of styryl lactone-derivatives and it can be found in the Kava plant (*Piper methysticum*). The Kava plant has a long and colorful history spanning several thousand years.⁴ Kava has been used by



Scheme 1. Retrosynthesis of kavain (**2**) and jerangolid D (**3**).

Pacific Island societies to prepare an intoxicating ceremonial beverage renowned for its relaxing effects and ability to promote sociability. Modern use of Kava root, commonly available in dietary supplements labeled ‘Kava Kava’, is mostly reported for its purported anxiolytic⁵ and soporific qualities. Analgesic,⁶ anesthetic, antifungal, antithrombotic,⁷ anticonvulsive,⁸ and muscle-relaxing⁹ properties have also been reported.⁴

Jerangolid D¹⁰ is a secondary metabolite produced by the myxobacterium *Sorangium cellulosum* (strain So ce 307), a myxobacterium isolated in 1987 in the soil of Jerusalem. In vitro tests suggested that jerangolid D might be a


* Corresponding author. Tel.: +32 10 472 740; fax: +32 10 472 788.
E-mail address: istvan.marko@uclouvain.be (I. E. Markó).

potentially useful antifungal agent, since it exhibits interesting activities against the developing cells of *Hansenula anomala* and *Mucor hiemalis* (~70 ng/mL); *Pichia membranaefaciens*, *Debaryomyces hansenii*, and *Trichosporon terrestris* (0.1–0.4 µg/mL); and *Trichoderma hamata*, *Botrytis cinerea*, and *Candida albicans* (4–7 µg/mL). The mechanism of its action is believed to be similar to that of ambruticin,¹¹ another well-known myxobacterium isolate, for which the mode of action is still unclear.


Our retrosynthesis of lactone **1** was designed to use the metathesis reaction as a key step (Scheme 2). As a consequence, lactone **1** was disconnected at the C2–C3 positions, leading to acrylate **4**. The required vinyl ether function present in **4** could then be prepared from ester **5** via titanium alkylidenation of the C3 carbonyl group.

The synthesis began with the selective reduction of the C6 ester of (*R*)-dimethyl malate **6** to the corresponding primary alcohol,¹² followed by the transformation of the resulting C6 alcohol¹³ into a TBS ether (Scheme 3). The remaining C5 alcohol was masked as a TMS ether and the resulting compound **8** was reacted with titanium alkylidene reagents. In our hands, Rainer's modification of the Takai–Utimoto reaction¹⁴ gave the best results,¹⁵ affording the desired enol ether **9** in 74% yield.

Finally, a selective one pot TMS group removal/base mediated esterification of the resulting C5 alkoxide accomplished the synthesis of the metathesis precursor **4**.



Scheme 2. Retrosynthesis of lactone **1**.



Scheme 3. Synthesis of metathesis precursor **4**.

Having established an easy access to the desired intermediate **4**, our first key step, the Grubbs' metathesis, could be challenged. From the literature precedents, it is known that the metathesis reaction of electron-rich olefins,¹⁶ in particular enol ethers, is rather difficult and requires harsh conditions, for example, prolonged reaction times, high temperatures and high catalyst loading. For this reason, the use of Schrock's more reactive, though more sensitive, catalyst¹⁷ is generally preferred.

The sensitivity of the Schrock carbene prompted us to perform our reactions using the 2nd generation Grubbs' catalyst (**GC-2**) in a non-polar solvent.^{16a} Thus, ester **4** was treated with **GC-2** in deuterated toluene and the influence of the reaction conditions on the conversion was monitored (Table 1).

It was observed that the metathesis reaction proceeded somewhat better at 50 °C (Table 1, entry 1) than at higher temperatures. In all cases, the catalyst was fully decomposed under the reaction conditions within 4–7 h. Therefore, constant addition of the catalyst over a period of 66 h (5 mol % of **GC-2** every 6 h) was performed. The starting material **4** gradually disappeared, yielding the desired lactone **10** in 88% yield (Table 1, entry 5). Unfortunately, up to 55 mol % of **GC-2** was consumed in this single experiment.

These results, though rather encouraging, could not be reconciled with our idea of a useful synthetic transformation. It was suggested that the low reactivity of **4** could be due, among other potential problems, to its difficulty in adopting an (*S*)-*cis* conformation and hence, enabling the two alkene termini to reach a proper distance for the reaction to occur.¹⁸ To overcome this problem and to reduce the catalyst loading, it was decided to use the modified metathesis precursor **11** (Fig. 1).¹⁹

The synthesis of **11** began with the monoprotected diol **7**, which was transformed into acetals **12a** and **12b** via

Table 1
Metathesis reaction of the precursor **4**

Entry	Conditions	Conversion ^a (%)	Yield ^a (%)
1	5 mol %, toluene- <i>d</i> ₈ , 12 h, 50 °C	20	20
2 ^b	5 mol %, toluene- <i>d</i> ₈ , 12 h, 60 °C	18	18
3 ^b	5 mol %, toluene- <i>d</i> ₈ , 12 h, 70 °C	10	10
4 ^c	5 mol %, toluene- <i>d</i> ₈ , 12 h, 80 °C	5	5
5 ^d	55 mol %, toluene- <i>d</i> ₈ , 66 h, 50 °C	91	88 ^e
6	10 mol %, toluene- <i>d</i> ₈ , 72 h, rt	8	<5


^a Based on ¹H NMR spectra.

^b Conversion stopped after 5–7 h.

^c Conversion stopped after 4 h.


^d 5 mol % of **GC-2** was added every 6 h.

^e Isolated yield.

Fig. 1. Alternative metathesis precursor **11**.

PPTS-catalyzed *trans*-acylation of acrolein diethyl acetal and methacrolein diethyl acetal,²⁰ respectively (Scheme 4). Acetals **12a** and **12b** were then submitted to the Takai–Utimoto olefination yielding the desired precursors **11a** and **11b** in 80% and 85% yields.

With the desired substrates in hand, the crucial ring closing metathesis could be tested again (Table 2). To our surprise, no important changes in the reactivity of **11a**, as

Scheme 4. Synthesis of precursor **11**.Table 2
RCM reaction of **11**

Entry	R	GC-2 loading (mol %)	Conditions	Yield ^a (%)
1	H	20 ^b	Benzene, 50 °C, 4 h	21
2	H	30 ^b	Benzene, 70 °C, 6 h	26
3	H	30 ^b	Toluene, 50 °C, 6 h	21
4	H	50	Benzene, rt, 24 h	39
5	H	10	Benzene, rt, 72 h	93
6	Me	10	Benzene rt, 84 h	95

^a Based on the ¹H NMR spectra.

^b 10 mol % of GC-2 was added every 2 h.

compared to substrate **4**, were observed (Table 2, entries 1–3).

The reaction proceeded with a slightly higher conversion, but the decomposition of the catalyst under the reaction conditions was still significant.

To avoid this decomposition, the reaction was attempted at rt. in the presence of 50 mol % of GC-2 (Table 2, entry 4). After 24 h, a 39% conversion of **11a** to cyclic acetal **13a** was reached. Allowing the cyclization to proceed longer led to improved conversions.


Under the optimized conditions, only 10 mol % of GC-2 was required to fully transform **11** to **13** (Table 2, entries 5 and 6).²¹ The oxidation of acetals **13** with PCC then afforded the desired lactones **10a** and **10b** in 56% and 51% yields, respectively, over two steps.

Removal of the TBS group of **10b** furnished alcohol **14b**, the left-hand fragment of jerangolid D (**3**), in 81% yield (Scheme 5).²²


The C2 desmethyl lactone **10a** was also deprotected (82% yield) and the resulting alcohol **14a** was then used in the synthesis of (*R*)-kavain **2** (Scheme 6). Thus, alcohol **14a** was transformed into aldehyde **1a** via Swern oxidation. Lactone **1a** was immediately reacted with benzyl phenyl sulfoxide under our sulfoxide–Julia olefination conditions²⁴ (Scheme 6), affording (*R*)-kavain **2** in 65% yield and with an excellent *E/Z* selectivity.

The necessity to employ the sulfoxide version of the Julia olefination reaction in this ultimate transformation had been discussed previously.^{24c}

In summary, the penultimate precursor of the left-hand fragment of jerangolid D, alcohol **14b**, was prepared in seven steps and 16% overall yield from commercially available dimethyl D-malate **6**. Similarly, (*R*)-kavain **2** was



Scheme 5. Synthesis of the C1–C6 fragment of jerangolid D.

Scheme 6. Total synthesis of (*R*)-kavain **2**.

synthesized in nine steps and in 7.7% overall yield. To achieve these goals, a simple approach toward 3-methoxy α,β -unsaturated lactones of the general structure **1**, based upon the metathesis reaction of electron-rich alkenes, coupled with our sulfoxide Julia olefination procedure was employed.

Acknowledgments

Financial support of this work by the Université catholique de Louvain, Rhodia Ltd (studentship to J.P.), Merck Sharp and Dohme (Merck Academic Development Award to I.E.M.) is gratefully acknowledged.

Supplementary data

Supplementary data associated with this article can be found, in the online version, at [doi:10.1016/j.tetlet.2007.12.113](https://doi.org/10.1016/j.tetlet.2007.12.113).

References and notes

- For a review see: Collins, I. *J. Chem. Soc., Perkin Trans. 1* **1999**, 1377–1395; For recent examples see: (a) Pospíšil, J.; Markó, I. E. *Tetrahedron Lett.* **2006**, *47*, 5933–5937; (b) Gobbin, M.; Cerri, A. *Curr. Med. Chem.* **2005**, *12*, 2343–2355; (c) de Fatima, A.; Pilli, R. A. *Tetrahedron Lett.* **2003**, *44*, 8721–8724; (d) de Fatima, A.; Pilli, R. A. *ARKIVOC* **2003**, *10*, 118–126; (e) Bruckner, R. *Curr. Org. Chem.* **2001**, *5*, 679–718; (f) Job, A.; Wolberg, M.; Muller, M.; Enders, D. *Synlett* **2001**, 1796–1798.
- (a) Zhao, G.; Wu, B.; Wu, X. Y.; Zhang, Y. Z. *Mini-Rev. Org. Chem.* **2005**, *2*, 333–354; (b) Yet, L. *Chem. Rev.* **2003**, *103*, 4283–4306; (c) Mereyala, H. B.; Joe, M. *Curr. Med. Chem. – Anti-Cancer Agents* **2001**, *1*, 293–300.
- (a) Leclercq, C.; Markó, I. E. *Tetrahedron Lett.* **2005**, *46*, 7229–7233; (b) De Dobbeleer, C.; Ates, A.; Vanherk, J.-C.; Markó, I. E. *Tetrahedron Lett.* **2005**, *46*, 3889–3893; (c) Markó, I. E.; Dumeunier, R.; Leclercq, C.; Leroy, B.; Plancher, J.-M.; Mekhalifa, A.; Bayston, D. J. *Synthesis* **2002**, 958–972.
- Lebot, V.; Merlin, M.; Lindstrom, L. *Kava-the Pacific Elixir: The Definitive Guide to its Ethnobotany, History, and Chemistry*; Healing Arts Press: Rochester, VT, 1997.
- (a) Pittler, M. H.; Ernst, E. *J. Clin. Psychopharm.* **2000**, *20*, 84–89; (b) Smith, K. K.; Dharmaratne, H. R. W.; Feltenstein, M. W.; Broom, S. L.; Roach, J. T.; Nanayakkara, N. P. D.; Khan, I. A.; Sufka, K. J. *Psychopharmacology* **2001**, *155*, 86–90.
- (a) Jamieson, D. D.; Duffield, P. H. *Clin. Exp. Pharmacol. Physiol.* **1990**, *17*, 495–500; (b) Wu, D.; Yu, L.; Nair, M. G.; DeWitt, D. L.; Ramsewak, R. S. *Phytomedicine* **2002**, *9*, 41–47.
- Gleitz, J.; Beile, A.; Wilkens, P.; Ameri, A.; Peters, T. *Planta Med.* **1997**, *63*, 27–30.
- Schmitz, D.; Zhang, C. L.; Chatterjee, S. S.; Heinemann, U. *Arch. Pharmacol. Toxicol.* **1995**, *351*, 348–355.
- Seitz, U.; Ameri, A.; Pelzer, H.; Gleitz, J.; Peters, T. *Planta Med.* **1997**, *63*, 303–306.
- (a) Reichenbach, H.; Höfle, G.; Gerth, K.; Washausen, P. *PCT Int. Appl.* 1997, DE 19607702, CAN 127:219644; (b) Gerth, K.; Washausen, P.; Höfle, G.; Irschik, H.; Reichenbach, H. *J. Antibiot.* **1996**, *49*, 71–75.
- (a) Ringel, S. M.; Greenough, R. C.; Roemer, S.; Connor, D.; Gutt, A. L.; Blair, B.; Kanter, G.; von Strandmann, M. *J. Antibiot.* **1977**, *30*, 371–378; (b) Connor, D. T.; Greenough, R. C.; von Strandmann, M. *J. Org. Chem.* **1977**, *42*, 3664–3669; (c) Knauth, P.; Reichenbach, H. *J. Antibiot.* **2000**, *53*, 1182–1190.
- (a) Saito, S.; Hasegawa, T.; Inaba, M.; Nishida, R.; Fujii, T.; Nomizu, S.; Moriwake, T. *Chem. Lett.* **1984**, 1389–1392; (b) Saito, S.; Ishikawa, T.; Kuroda, A.; Koga, K.; Moriwake, T. *Tetrahedron* **1992**, *48*, 4067–4086.
- Alcohol **7** was obtained as a 12:1 mixture of the C6 and C5 monosilylated diols. See Table S-1 (Supplementary information).
- (a) Okazoe, T.; Takai, K.; Oshima, K.; Utimoto, K. *J. Org. Chem.* **1987**, *52*, 4410–4412; (b) Allwein, S. P.; Cox, J. M.; Howard, B. E.; Johnson, H. W. B.; Rainier, J. D. *Tetrahedron* **2002**, *58*, 1997–2009.
- For the reaction optimization, see Table S-2 (Supplementary information).
- (a) Okada, A.; Ohshima, T.; Shibasaki, M. *Tetrahedron Lett.* **2001**, *42*, 8023–8027; Use in total synthesis (b) Holson, E. B.; Roush, W. R. *Org. Lett.* **2002**, *4*, 3719–3722; (c) Taillier, C.; Gille, B.; Bellosta, V.; Cossy, J. *J. Org. Chem.* **2005**, *70*, 2097–2108; (d) Majumder, U.; Cox, J. M.; Johnson, H. W. B.; Rainier, J. D. *Chem. Eur. J.* **2006**, *12*, 1736–1746; (e) Johnson, H. W. B.; Majumder, U.; Rainier, J. D. *Chem. Eur. J.* **2006**, *12*, 1747–1753.
- Schrock, R. R. *Tetrahedron* **1999**, *55*, 8141–8153.
- Trnka, T. M.; Grubbs, R. H. *Acc. Chem. Res.* **2001**, *34*, 18–29.
- Stork, G.; Mook, R., Jr.; Biller, S. A.; Rychnovsky, S. D. *J. Am. Chem. Soc.* **1983**, *105*, 3741–3742. Alternatively, initial reaction of **GC-2** with the enol ether function rather than the acrylate might lead to a poorly active Fisher-type carbene. By shifting to an acetal, preferential addition on C1–C2 takes place.
- VanAllan, J. A. *Org. Synth.* **1952**, *32*, 5–8.
- Interestingly, the same reaction conditions were applied to the cyclization of **4**, but only very low conversion (~20%) was observed.
- For an alternative synthesis, leading to the jerangolid D C1–C6 fragment, see: Pospíšil, J.; Markó, I. E. *J. Am. Chem. Soc.* **2007**, *129*, 3516–3517.
- Previous total synthesis of (*R*)-kavain **2** (a) Smith, T. E.; Djang, M.; Velder, A. J.; Downey, C. W.; Carroll, K. A.; Alphen, S. V. *Org. Lett.* **2004**, *6*, 2317–2320; (b) Wang, F.-D.; Yue, J.-M. *Synlett* **2005**, 2077–2079; (c) Sabitha, G.; Sudhakar, K.; Yadav, J. S. *Tetrahedron Lett.* **2006**, *47*, 8599–8602.
- (a) Pospíšil, J.; Pospíšil, T.; Markó, I. E. *Org. Lett.* **2005**, *7*, 2373–2376; (b) Pospíšil, J.; Pospíšil, T.; Markó, I. E. *Collect. Czech Chem. Commun.* **2005**, *70*, 1953–1969; (c) Pospíšil, J.; Markó, I. E. *Tetrahedron Lett.* **2006**, *47*, 5933–5937.
- Experimental data for (*R*)-(+)-kavain **2**: ¹H NMR (300 MHz, CDCl₃) δ (ppm): 2.55 (dd, 1H, *J* = 17.1 Hz, *J* = 4.6 Hz), 2.68 (dd, 1H, *J* = 17.1 Hz, *J* = 10.7 Hz), 3.77 (s, 3H), 5.06–5.09 (m, 1H), 5.20 (s, 1H), 6.27 (dd, 1H, *J* = 16.1 Hz, *J* = 6.3 Hz), 6.73 (d, 1H, *J* = 16.0 Hz), 7.29–7.41 (m, 5H). ¹³C NMR (75 MHz, CDCl₃) δ (ppm): 33.8, 56.5, 76.5, 91.1, 125.8, 133.2, 167.2, 127.0, 128.8, 129.2, 136.3, 172.6. Mp = 113–114 °C; lit. 112–113 °C.^{23a} IR (KBr) ν (cm⁻¹): 3063, 2967, 1703, 1626, 1394, 1248, 1233, 1063, 1024, 971, 747, 693. [α]_D²⁰ +120.3 (c 1.02, EtOH); lit. [α]_D²⁵ +124.3 (c 1.00, EtOH).^{23a}